Bayer says Warner Chilcott's birth control steps on its patent; study raises issue over some use of Misoprostol;

 @FiercePharma: China significantly ratchets back drugs on 'essential drugs' list. More | Follow @FiercePharma

> Bayer has filed a complaint against U.S. group Warner Chilcott ($WCRX) saying the company is stepping on its patent with its sale of its contraceptive Lo Loestrin. Item

> The FDA has given Indian drugmaker Wockhardt approval to make a generic version of Orion's Comtan for the treatment Parkinson's disease. Story

> A new study says the World Health Organization needs to consider dropping approval of Misoprostol, made in generic form and by Pfizer ($PFE) as Cytotec, for treatment of bleeding after childbirth, saying there is no evidence it works in that case. Story

> Telstar finished construction of a 30,000-square-meter manufacturing plant with three production lines in Barcelona, Spain. Story

> Watson Pharmaceuticals ($WPI) has hit the market with its authorized generic of version of Sunovion Pharmaceuticals' Xopenex, a respiratory disease drug. Item

>  Cambrex Charles City announced a $19 million construction project to increase its API manufacturing and that could lead to 45 to 60 new jobs over the next three years. Story

Medical Device News

@FierceMedDev: Looks like the U.S. endoscopy device market will double over the next 6 years. Release | Follow @FierceMedDev

 @MarkHFierce: A CMS coverage decision could reduce the amount of cardiac implants hospitals perform each year, says a new survey. More | Follow @MarkHFierce

 @DamianFierce: Developers look for FDA approval for medical device-like apps. Article | Follow @DamianFierce

> Report: North American endoscopy sales will soar to $4.3 billion by 2017. Report

> Investors punish Brazil's Dasa for turmoil and sluggish Dx sales. Item

> Another variation from Abbott's Xience stent line wins CE mark. Story

Biotech News

 @FierceBiotech: Check out's 10 Big Pharma smartphone apps slideshow. Special Feature | Follow @FierceBiotech

 @JohnCFierce: J&J forking over another $50M milestone to Pharmacyclics for their btk partnership. Now that's how you reap biobucks. Release | Follow @JohnCFierce

 @RyanMFierce: DNA data-crunching contest draws Sanofi, NIH, others. Report | Follow @RyanMFierce

> Booming Pharmacyclics snags $50M paycheck as J&J pact drives blood cancer trials. More

> FDA calendar crowded with blockbuster decisions for Ironwood, Pfizer and Sanofi. News

> New lab organs promise faster, cheaper, better drug development. Report

> Regulus Therapeutics files for $58M IPO. Story

CRO News

> Report: 211 died in Indian trials in first half of 2012. More

> Icon banks on translational medicine with U.K. expansion. Item

> CROs: Go green to woo Pfizer. More

> INC picks three of its own for new C-level spots. Report

> Report: Indian CRO market will double, reach $1B in 2016. Story

Biotech IT News

> DNA data-crunching contest draws Sanofi, NIH, others. Story

> Lilly's 'big data' ally finds new Indy digs for IT workers. More

> Big data analytics bolsters hunt for elusive Huntington's drugs. Article

> Quintiles gains genomic, bioinformatics know-how in buyout. Item

And Finally... China's new blacklist of drugmakers set to launch Oct. 1 will include drug companies found to use bribery to get drug approvals as well as those found to be making substandard or counterfeit drugs. Story